Back to Search Start Over

AHR Regulates NK Cell Migration via ASB2-Mediated Ubiquitination of Filamin A.

Authors :
Shin JH
Moreno-Nieves UY
Zhang LH
Chen C
Dixon AL
Linde MH
Mace EM
Sunwoo JB
Source :
Frontiers in immunology [Front Immunol] 2021 Feb 24; Vol. 12, pp. 624284. Date of Electronic Publication: 2021 Feb 24 (Print Publication: 2021).
Publication Year :
2021

Abstract

Natural killer (NK) cells are effector cells of the innate immune system involved in defense against virus-infected and transformed cells. The effector function of NK cells is linked to their ability to migrate to sites of inflammation or damage. Therefore, understanding the factors regulating NK cell migration is of substantial interest. Here, we show that in the absence of aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, NK cells have reduced capacity to migrate and infiltrate tumors in vivo . Analysis of differentially expressed genes revealed that ankyrin repeat and SOCS Box containing 2 ( Asb2 ) expression was dramatically decreased in Ahr <superscript>-/-</superscript> NK cells and that AhR ligands modulated its expression. Further, AhR directly regulated the promoter region of the Asb2 gene. Similar to what was observed with murine Ahr <superscript>-/-</superscript> NK cells, ASB2 knockdown inhibited the migration of human NK cells. Activation of AHR by its agonist FICZ induced ASB2-dependent filamin A degradation in NK cells; conversely, knockdown of endogenous ASB2 inhibited filamin A degradation. Reduction of filamin A increased the migration of primary NK cells and restored the invasion capacity of AHR-deficient NK cells. Our study introduces AHR as a new regulator of NK cell migration, through an AHR-ASB2-filamin A axis and provides insight into a potential therapeutic target for NK cell-based immunotherapies.<br />Competing Interests: JBS is the scientific co-founder and member of the scientific advisory board of Indapta Therapeutics; however, the science presented here is not related to the focus of the company. UM-N is the founder of Conference Fund; however, the science presented here is not related to the focus of the company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Shin, Moreno-Nieves, Zhang, Chen, Dixon, Linde, Mace and Sunwoo.)

Details

Language :
English
ISSN :
1664-3224
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
33717133
Full Text :
https://doi.org/10.3389/fimmu.2021.624284